These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11762934)

  • 1. Long-term morbidity, mortality, and economics of rheumatoid arthritis.
    Wong JB; Ramey DR; Singh G
    Arthritis Rheum; 2001 Dec; 44(12):2746-9. PubMed ID: 11762934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study.
    Tanaka E; Inoue E; Mannalithara A; Bennett M; Kamitsuji S; Taniguchi A; Momohara S; Hara M; Singh G; Yamanaka H
    Mod Rheumatol; 2010 Feb; 20(1):46-53. PubMed ID: 19821162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA.
    Tanaka E; Hoshi D; Igarashi A; Inoue E; Shidara K; Sugimoto N; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Tsutani K; Yamanaka H
    Mod Rheumatol; 2013 Jul; 23(4):742-51. PubMed ID: 22878927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis.
    Wong JB; Singh G; Kavanaugh A
    Am J Med; 2002 Oct; 113(5):400-8. PubMed ID: 12401535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.
    Tanaka E; Inoue E; Hoshi D; Shimizu Y; Kobayashi A; Sugimoto N; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2015 Jul; 25(4):503-13. PubMed ID: 25547018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.
    Kobelt G; Jönsson L; Young A; Eberhardt K
    Rheumatology (Oxford); 2003 Feb; 42(2):326-35. PubMed ID: 12595631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.
    Kobelt G; Lindgren P; Lindroth Y; Jacobson L; Eberhardt K
    Rheumatology (Oxford); 2005 Sep; 44(9):1169-75. PubMed ID: 15956093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis.
    Welsing PM; Severens JL; Hartman M; van Gestel AM; van Riel PL; Laan RF
    Pharmacoeconomics; 2006; 24(10):1011-20. PubMed ID: 17002483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.
    Lekander I; Borgström F; Svarvar P; Ljung T; Carli C; van Vollenhoven RF
    Int J Technol Assess Health Care; 2010 Jan; 26(1):54-61. PubMed ID: 20059781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
    Kobelt G; Lindgren P; Singh A; Klareskog L
    Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "5D" Outcome in 52 patients with rheumatoid arthritis surviving 20 years after initial disease modifying antirheumatic drug therapy.
    Capell H; McCarey D; Madhok R; Hampson R
    J Rheumatol; 2002 Oct; 29(10):2099-105. PubMed ID: 12375318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis: Observational Data from Southern Sweden.
    Wallman JK; Eriksson JK; Nilsson JÅ; Olofsson T; Kristensen LE; Neovius M; Geborek P
    J Rheumatol; 2016 Jul; 43(7):1292-9. PubMed ID: 27252420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
    Hamuryudan V; Direskeneli H; Ertenli I; Inanc M; Karaaslan Y; Oksel F; Ozbek S; Pay S; Terzioglu E; Balkan Tezer D; Hacibedel B; Akkoc N
    Clin Exp Rheumatol; 2016; 34(6):1033-1037. PubMed ID: 27749224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A multicenter cross-sectional study on the health related quality of life of patients with rheumatoid arthritis using a revised Japanese version of the arthritis impact measurement scales version 2 (AIMS 2), focusing on the medical care costs and their associative factors].
    Hashimoto A; Sato H; Nishibayahi Y; Shiino Y; Kutsuna T; Ishihara Y; Hoshi K; Fujimori J; Tsuboi S; Kondo H; Akizuki M; Moroi Y; Yoshida S
    Ryumachi; 2002 Feb; 42(1):23-39. PubMed ID: 11925904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic consequences of the progression of rheumatoid arthritis in Sweden.
    Kobelt G; Eberhardt K; Jönsson L; Jönsson B
    Arthritis Rheum; 1999 Feb; 42(2):347-56. PubMed ID: 10025930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis.
    Michaud K; Strand V; Shadick NA; Degtiar I; Ford K; Michalopoulos SN; Hornberger J
    Rheumatology (Oxford); 2015 Sep; 54(9):1640-9. PubMed ID: 25877911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis.
    Kobelt G; Jönsson L; Lindgren P; Young A; Eberhardt K
    Arthritis Rheum; 2002 Sep; 46(9):2310-9. PubMed ID: 12355478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
    Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.